----item----
version: 1
id: {1926D5B9-94D8-4A1D-910C-7D787B488D9B}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/09/LongTerm Scleroderma Data Support Cytoris Phase III Plans
parent: {A1488DBB-C468-4AE3-BA7B-6FC254EF9442}
name: LongTerm Scleroderma Data Support Cytoris Phase III Plans
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 213882f5-b1b5-41c5-a14c-66510d017843

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 155

{1D288E18-BAFF-4498-B284-EF9BC8D32E30}|{3B33748A-17E9-4241-8447-989BB3484DFB}|{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{29C8E5B9-B01E-4DEE-A123-14D70756095B}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 59

Long-Term Scleroderma Data Support Cytori's Phase III Plans
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 57

LongTerm Scleroderma Data Support Cytoris Phase III Plans
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2276

<p>Twelve scleroderma patients experienced long-term improvement of their rare skin disease symptoms after a single administration of the Cytori Therapeutics cell therapy ECCS-50 in an investigator-initiated, open-label study published in the journal <i>Rheumatology</i> on Sept. 8.</p><p>San Diego-based Cytori used the clinical trial results to justify initiation of an 80-patient Phase III clinical trial in August to support US FDA approval and the company expects a European Phase III trial to begin before the end of 2015. Cytori's stock closed up 17.3% at $0.48 per share. The company's stock has been battered since the summer of 2014 after Cytori was forced to halt its clinical trials in heart failure patients due to cerebrovascular events.</p><p>While <a href="http://www.scripintelligence.com/policyregulation/Cytori-soars-after-FDA-permits-ATHENA-to-move-forward-354637" target="_new">the FDA eventually allowed</a> the ATHENA and ATHENA II trials in heart failure to continue, Cytori no longer is pursuing that indication, which means the <a href="http://www.scripintelligence.com/business/Cell-therapy-developer-Cytori-restructuring-cutting-42-jobs-354069" target="_new">slimmed down company's</a> autologous cell therapy for scleroderma is now its lead development program. </p><p>At 12 months after a single treatment of ECCS-50, scleroderma patients in the small investigator-sponsored study experienced average reductions of 51.3% and 46.8% in hand function measures known as the Cochin Hand Function Scale and the Scleroderma Health Activity Questionnaire (p<0.001 for="" both).="" the="" incidence="" and="" severity="" of="" raynaud's="" syndrome="" declined="" by="" 63.2%="" from="" baseline="" on="" average=""></0.001><0.001), grip="" strength="" improved="" 30.5%="" (p="0.002)" and="" pain="" was="" reduced="" by="" 34.5%=""></0.001),><0.001). fibrosis="" and="" vascular="" suppression="" also=""></0.001).></p><p>Scleroderma is a chronic autoimmune disease that causes hardening of the skin. There are no approved treatments and aside from ECCS-50 there are only seven drugs in Phase I and II development. Cytori's ECCS-50 study in the US is being conducted under an investigational device exemption (IDE) granted by the FDA.</p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 286

<p>Twelve scleroderma patients experienced long-term improvement of their rare skin disease symptoms after a single administration of the Cytori Therapeutics cell therapy ECCS-50 in an investigator-initiated, open-label study published in the journal <i>Rheumatology</i> on Sept. 8.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 57

LongTerm Scleroderma Data Support Cytoris Phase III Plans
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150909T042732
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150909T042732
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150909T042732
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029728
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 59

Long-Term Scleroderma Data Support Cytori's Phase III Plans
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198800586
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{B322F30F-1522-4633-91A4-A2EF3216848C}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360304
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042447Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

213882f5-b1b5-41c5-a14c-66510d017843
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042447Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
